By Syndicated Content
By Carl OâDonnell and Trisha Roy
(Reuters) -The U.S. Food and Drug Administration could potentially have done more to avoid the current controversies around its accelerated approval of Biogen Incâs Alzheimerâs drug, Aduhelm, FDA acting Commissioner Janet Woodcock said during a Wednesday summit hosted by Stat.
The FDA last week called for an independent federal probe into its representativesâ interactions with Biogen ahead of the regulatorâs approval of Aduhelm last month.
âThe accelerated approval was based on very solid grounds,â Woodcock said during Statâs Breakthrough Science Summit.
However, she said, âIt is possible the process could have been handled in a way that would have decreased the amount of controversy involved.â
New-york
United-states
Bengaluru
Karnataka
India
American
Leslie-adler
Trisha-roy
Janet-woodcock
Carl-odonnell
Biogen-inc-alzheimer
Twitter